IL33 and neoplasm: Our clinical study on human prostate tumors (Figure 7) demonstrates the direct correlation between eosinophilic infiltration and IL-33-expression, suggesting the contribution of the IL-33/ILC2 axis to anti-tumor immune responses at earlier stages of human prostate carcinoma.